Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.

Nature communications - 1 May 2020

Liu Xian-De, Kong Wen, Peterson Christine B, McGrail Daniel J, Hoang Anh, Zhang Xuesong, Lam Truong, Pilie Patrick G, Zhu Haifeng, Beckermann Kathryn E, Haake Scott M, Isgandrova Sevinj, Martinez-Moczygemba Margarita, Sahni Nidhi, Tannir Nizar M, Lin Shiaw-Yih, Rathmell W Kimryn, Jonasch Eric

Abstract excerpt

A non-immunogenic tumor microenvironment (TME) is a significant barrier to immune checkpoint blockade (ICB) response. The impact of Polybromo-1 (PBRM1) on TME and response to ICB in renal cell carcinoma (RCC) remains to be resolved. Here we show that PBRM1/Pbrm1 deficiency reduces the binding of brahma-related gene 1 (BRG1) to the IFNγ receptor 2 (Ifngr2) promoter, decreasing STAT1 phosphorylation and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen-Antibody Complex
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorescent Antibody Technique

Share to Kidney Neoplasms

Share to Mice, Inbred BALB C

Share to STAT1 Transcription Factor

Share to Tissue Array Analysis

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 32358509
DOI: 10.1038/s41467-020-15959-6
PMCID: PMC7195420

Genes

PBRM1
STAT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.PMID 32358509Read ↗

<i>PBRM1</i> loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinomaSemantic proximity Read ↗

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancersSemantic proximity Read ↗

Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinomaSemantic proximity Read ↗

PBRM1 bromodomains variably influence nucleosome interactions and cellular function.Semantic proximity Read ↗

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL <sup>−/−</sup> clear cell renal carcinomaSemantic proximity Read ↗

An enhancer demethylator phenotype tightly associated with immune exhaustion and resistance to immune checkpoint inhibitors in clear-cell renal cell carcinomasSemantic proximity Read ↗

In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice.Semantic proximity Read ↗

CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.Semantic proximity Read ↗

Distinct functions of <i>PBRM1</i> and <i>BAP1</i> reconcile the course of kidney cancer evolution and disease progressionSemantic proximity Read ↗

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancerSemantic proximity Read ↗

Loss of PBRM1 expression is associated with renal cell carcinoma progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.